Recording Baseline Refraction at Diagnosis
Placeholder: first exam sets the reference point for tracking.
- 6–9 yrs: Typical onset age (placeholder summary)
- -1.00 D: Baseline refraction (placeholder summary)
- strong: Axial length link (placeholder summary)
- 2-3x: Family history risk (placeholder summary)
Why baseline measurement matters
Placeholder line explaining baseline cycloplegic refraction importance.
Modeling the Untreated Progression Curve
Placeholder: unmanaged myopia progresses fastest in early years.
- -0.75 D/yr: Untreated rate (placeholder summary)
- 8–12 yrs: Peak progression age (placeholder summary)
- elevated: High myopia risk (placeholder summary)
- higher: Retinal risk later (placeholder summary)
Natural history without intervention
Placeholder line describing untreated childhood myopia trajectory.
Glasses-Only Correction Compared to Active Control
Placeholder: glasses correct vision but barely slow progression.
- -0.65 D/yr: Glasses-only rate (placeholder summary)
- ~13%: Slowing vs untreated (placeholder summary)
- yes: Active methods needed (placeholder summary)
- emerging: Myopic defocus lenses (placeholder summary)
Limits of single-vision correction
Placeholder line noting why glasses alone underperform.
Comparative Efficacy of Atropine and Orthokeratology
Placeholder: both methods cut progression roughly in half.
- -0.30 D/yr: Atropine rate (placeholder summary)
- -0.35 D/yr: Ortho-K rate (placeholder summary)
- ~60%: Atropine efficacy (placeholder summary)
- ~53%: Ortho-K efficacy (placeholder summary)
Choosing between active methods
Placeholder line comparing compliance and side-effect tradeoffs.
Targeting Long-Term Refraction Stabilization
Placeholder: goal is a flat curve by late teens.
- ~16-18 yrs: Typical stabilization age (placeholder summary)
- as low as possible: Target final refraction (placeholder summary)
- annual: Continued monitoring (placeholder summary)
- reduced: Adult onset risk (placeholder summary)
Sustaining control into adolescence
Placeholder line on maintaining treatment until stabilization.